Another study elucidated the way in which antagonistic anti-EGFR nanobodies that were selected using the phage display technology effectively blocked the binding of endothelial growth factor (EGF) to EGFR and EGF-mediated signaling and delayed tumor outgrowth in vivo [178]. The gene discussed is EGF; the disease is neoplasm.